Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15916184 | 0.86 | CNR1 (0.51) | CNR1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL15917207 | 0.86 | CNR1 (0.51) | CNR1L3MBTL1LMNAMEN1KMT2A | |
| SCHEMBL4943200 | 0.83 | L3MBTL1 (0.64) | CNR1L3MBTL1MEN1KMT2ACYP3A4 | |
| SCHEMBL14990609 | 0.76 | ACHE (0.55) | LMNAMEN1KMT2AROCK2ROCK1 | |
| SCHEMBL14990608 | 0.76 | ACHE (0.55) | LMNAMEN1KMT2AROCK2ROCK1 | |
| SCHEMBL28626011 | 0.76 | KMT2A (0.56) | LMNAMEN1KMT2AROCK2ROCK1 | |
| SCHEMBL2832689 | 0.75 | HCRTR1 (0.49) | CNR1USP2TSHRALDH1A1 | |
| SCHEMBL2831523 | 0.75 | HSD11B1 (0.45) | CNR1USP2TSHRALDH1A1 | |
| SCHEMBL3830538 | 0.75 | TP53 (0.40) | CNR1L3MBTL1LMNATSHRALDH1A1 | |
| SCHEMBL31224057 | 0.75 | TP53 (0.40) | CNR1L3MBTL1LMNATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | ASTRAZENECA AB | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272745-A1 | Novel piperidine and piperazine derivatives | CYP3A5, IL5, ABCC5 | CNR1 384/4885L3MBTL1 4884/4885LMNA 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.